Flare Therapeutics Reports Positive Phase 1 Data for FX-909
Flare Therapeutics Inc. has announced promising early findings from Part A of its Phase 1 study of FX-909, a new oral small molecule designed to inhibit the peroxisome proliferator-activated receptor…